Investing.com -- Shares in Merck KGaA (ETR:MRCG) slumped by more than 10% on Tuesday after the drugmaker announced that it had discontinued a Phase III study evaluating its treatment for patients with head and neck cancer.
Most readers would already know that Merck KGaA's (ETR:MRK) stock increased by 4.5% over the past three months. Given...
Merck KGaA (MKGAF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.